1 March 2018

More positive data from the Ionis/Roche trial released today




Today Ionis and Roche have announced more details from the Huntingtin lowering trial.  The initial results was released in December […]

Continue Reading

20 September 2018

Breaking! NEW VARIANT OF JHD DISCOVERED – video!




New findings indicate that Juvenile Huntington's should be separated into two distinct categories, which in turn may be treated differently. [...]

Continue Reading

18 September 2018

Two important meetings in Vienna




From 13thto 16thof September, to important meetings took place in Vienna: the EHA Business Meeting and the EHDN Plenary Meeting. [...]

Continue Reading

29 August 2018

Race for awareness – video!




18th of August the cycling race Géants Des Ardennes took place in Liège, Belgium. With the help of team leader Jeroen de [...]

Continue Reading

16 August 2018

Learn more about patient advocacy and how to influence!




Are you between 18 to 35, living in Europe and affected by a neurological disorder? Then you can participate in […]

Continue Reading

3 August 2018

Accelerated evaluation of drug




The European Medicines Agency has acknowledged the huntingtin lowering drug, RG6042 (previously known as IONIS-HTTRx), as a possible therapy that […]

Continue Reading

26 July 2018

EFNA Survey: need for increased awareness




A newly published survey conducted by EFNA, shows that young Europeans with neurological conditions lives with a fear of isolation […]

Continue Reading

6 July 2018

Huntington’s Disease Youth Organization needs you!




HDYO is looking to hold a review meeting on the future direction of the Young Adult Working Group of EHDN […]

Continue Reading

4 July 2018

News from EHDN




Read about the Registery journey from the very beginning to the more recent successor study Enroll-HD. Cristina Ferreira gives you […]

Continue Reading

13 June 2018

An exciting new therapy




Wave is currently testing a new treatment known as ‘Precision medicine’. The drug only targets the disease-causing protein and leaves [...]

Continue Reading

8 June 2018

A letter from Roche




Roche Pharmaceuticals is currently working on their Huntingtin Lowering drug, RG6042 (formerly known as IONIS-HTTRx). In the letter Patient Partnership […]

Continue Reading

Events

There are no upcoming events.

Funding Partner